Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2313MR)

This product GTTS-WQ2313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2313MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1587MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ6399MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ8153MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ1995MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ2436MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ13490MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ11674MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ13816MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW